Business Overview

Active

2008

68

$88M

Funding Round

5

12

2.2 years

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals while evaluating additional tests for other high-risk diseases.

Employee Count

1.3%

Employee counts updated on a monthly basis.

Lists

News

Stock Chart

Founders (1)

NamePositionMilitaryClassificationContact
hiddenAdam Wasserstrom
VP Software & Analytics

AI Team (0)

Board and Advisors (1)

NamePositionContact
hiddenErez Chimovits
Partner and Board Member

Revenues (0)

Funding Rounds (5)

$85M

RoundDateCapital RaisedValuationInvestors
January 2022
hidden$22M
4
April 2021
hidden$55M
10
July 2018
hidden$3M
1
May 2016
hidden$3M
3
June 2014
hidden$5M
2

M&A Events (0)

Investors (12)

InvestorInvestor TypeLocation
hiddenHorizon 2020
GovernmentEurope
hiddenOrbiMed
Venture CapitalUnited States
hiddenZohar Zisapel
AngelIsrael
hiddenRA Capital
Venture CapitalUnited States
hiddenBlackRock
Investment FirmUnited States
hiddenAurum Ventures MKI
Family OfficeIsrael
hiddenLilly Asia Ventures
Venture CapitalChina
hiddenLYFE Capital
Venture CapitalChina
hiddenMILFAM
Family OfficeUnited States
hiddenOCI Bio Investments
Corporate Venture CapitalSouth Korea
hiddenDSC Investment
Venture CapitalUnited States
hiddenSands Capital Ventures
Venture CapitalUnited States

Patents (0)

Research Publications (0)

Certifications (1)

TitleDateCertification Type
March 2017CE

AI Technology Stack

Combining big data analysis and unique Machine Learning algorithms we construct optimal biomarker panels. Constructing an optimal panel of biomarkers is the art of “signal vs. noise”. Additional markers can improve the sensitivity by detecting more sick patients, but also can decrease specificity by detecting more normal samples. We use powerful bioinformatics big data and machine learning algorithms to construct “synergistic” panels that can evolve until the optimal result is achieved.

Jobs (0)

NameStatusFoundedStageFundingValuationEmployees1YR Headcount GrowthFounder UnitsFounder Classification

Pro Lite Subscription Required

Unlock all profile details

With a Pro Lite subscription, you can enjoy unlimited profile viewing with access to hidden details. Power your innovation efforts, uninterrupted.

$20/month

cancel anytime

Pro Lite includes:

Pro Subscription Required

View all verified emails

With a Pro subscription, you can enjoy unlimited profile viewing, export our entire database, and view verified email contacts. Power your innovation efforts, uninterrupted.

$50/month

cancel anytime

Pro includes:

StartupHub.ai

StartupHub.ai, the hub of the AI startup ecosystem.

Add or Claim Your Profile

Submit the form below to add or claim an existing profile. Within 24 hours, we'll review your request and connect you to your existing profile for full editing.

Pro Lite Subscription Required

Unlock all search results

With a Pro Lite subscription, you can enjoy unlimited profile viewing. Power your innovation efforts, uninterrupted.

$20/month

cancel anytime

Pro Lite includes: